ReGenTree is focused on developing innovative ophthalmic products, particularly targeting dry eye syndrome and neurotrophic keratopathy. The company's lead product, RGN-259, is a preservative-free ophthalmic solution formulated with Thymosin β4 (Tβ4), a naturally occurring regenerative protein. Tβ4 is a synthetic 43-amino acid peptide that plays a crucial role in promoting corneal epithelial cell migration, reducing inflammation, and enhancing repair and regeneration processes in the eye. This formulation is designed to meet the needs of patients requiring daily eye care, ensuring both efficacy and convenience.

The proprietary technology behind RGN-259 includes advanced manufacturing techniques and blow-fill-seal technology, which are implemented in a cGMP-compliant facility to ensure high-quality production standards. ReGenTree is currently conducting Phase III clinical trials for both dry eye syndrome and neurotrophic keratopathy, demonstrating its commitment to advancing ophthalmic therapeutics. The company aims to establish itself as a leader in the pharmaceutical industry for eye disorders by leveraging its innovative approach and proprietary technologies.

United States

ReGenTree, LLC is a newly created U.S. joint venture company owned by HLB Therapeutics (formerly GtreeBNT Co., Ltd.), a bio venture company in Korea. The company was founded with the aim of becoming a global leader in the pharmaceutical industry for ophthalmic disorders.

ReGenTree

Company Details